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Edited by Laszlo NagyAbstract Human resistin, found within atheroma, exerts
inﬂammatory, angiogenic and proliferative eﬀects in vascular
cells and may predict coronary events. Here, we investigate
mechanisms by which resistin contributes to macrophage ‘foam
cell’ formation. Increases in macrophage (THP-1) cholesteryl es-
ter mass, in the presence or absence of oxidized LDL, were not
explained by altered cholesterol eﬄux. Instead, resistin enhanced
fractional turnover of the endogenous triacylglycerol pool, in-
creased uptake and decreased oxidation of exogenous fatty
acids, and decreased phosphorylation of acetyl CoA carboxylase,
all factors increasing the availability of fatty acyl CoA substrate
for acyl CoA: cholesterol acyltransferase-1, thereby enhancing
macrophage cholesteryl ester deposition.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Resistin/FIZZ 3 (found in inﬂammatory zone 3) belongs to
a new gene family of small cysteine-rich secretory proteins,
called ‘resistin-like molecules’ (RELMS), originally discov-
ered in a search for adipocyte-derived molecules linking obes-
ity and insulin-resistant diabetes [1]. In rodents, resistin
derives largely from adipose tissue [2], impairs glucose toler-
ance, hepatic and/or peripheral insulin sensitivity [3,4], inhib-
its fatty acid oxidation and induces lipid accumulation in
skeletal muscle [5]. The mechanism of action is not fully
understood, as the putative resistin receptor remains uniden-
tiﬁed, but appears to involve repression of 5 0-AMP activated
kinase [2–5], which acts as an ‘energy sensor’ in cells and
tissues.
Human resistin shows signiﬁcant sequence and tissue diver-
gence from its murine counterpart [2]: it is expressed at lowAbbreviations: ACAT-1, acyl CoA: cholesterol acyltransferase-1; apo,
apolipoprotein; ABCA1, ATP binding cassette transporter A1; ACC,
acetyl CoA carboxylase; CoA: AMPK, 50AMP-activated protein
kinase; Coenzyme A; OxLDL, oxidized LDL; RELMS, resistin-like
molecules
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doi:10.1016/j.febslet.2007.09.014levels in adipose tissue and has not, as yet, been convincingly
linked with adiposity, insulin resistance or type II diabetes
[6]. Instead, this cytokine is predominantly expressed in bone
marrow and circulating monocytes and up-regulated during
monocyte–macrophage diﬀerentiation [2,7]. Accumulating
evidence suggests that resistin may not only be secreted by
macrophages within atheromatous tissue, but also predict
and actively promote lesion progression. Immunohistochemi-
cal studies ﬁnd carotid endartectomy samples, but not
healthy internal mammary artery, stain positively for resistin
[8–10]. Resistin mRNA and protein have been detected in the
center of abdominal aortic aneurysms with atheromatous pla-
que and calciﬁcation and plasma levels of resistin are re-
ported to be higher in patients diagnosed with premature
coronary disease, correlate with markers of inﬂammation
and, in some studies, predict coronary artery disease [7–10].
Resistin induces angiogenic [11], inﬂammatory [12–15] and
proliferative [16] responses in human vascular cells, mediated
by activation of nuclear factor-jB [12–15] and ERK1/2
[11,16] signal transduction pathways, and expression of
resistin is induced by inﬂammatory cytokines [14,15] and
oxidized low-density lipoprotein (OxLDL) [17] in human
macrophages, sustaining and exacerbating the inﬂammatory
response.
Intriguingly, however, recent evidence suggests conservation
of function between human and murine resistin, despite their
diﬀering sites of expression [2]. Murine resistin initiates chronic
inﬂammatory conditions, such as rheumatoid arthritis [15],
and resistin mRNA and protein are found within atheroma-
tous lesions in apoE(/) mice [8]. Both murine and human
resistin impair insulin action in murine cardiomyocytes, pro-
viding further evidence for functional homology [18]. Thus,
resistin secreted by macrophages within human atheromatous
lesions, might play a signiﬁcant metabolic role within the
artery wall, promoting lipid accumulation and contributing
to plaque instability. Indeed, our preliminary work in human
(THP-1) macrophages, which do not express or secrete resistin
but remain responsive to this cytokine, showed that recombi-
nant human resistin can induce increases in total cholesterol
and triacylglycerol mass, in the absence of native or modiﬁed
lipoproteins [19]; triacylglycerol accumulation was inhibited
by established activators of 5 0-AMP activated protein kinase
(AMPK) [19]. Here, we investigate the metabolic mechanisms
underlying our key ﬁnding: that chronic treatment with phys-
iological concentrations of resistin enhances cholesterol esteri-
ﬁcation and increases cholesteryl ester mass in human (THP-1)
macrophages, in the presence or absence of oxidized low-
density lipoprotein (OxLDL).blished by Elsevier B.V. All rights reserved.
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2.1. Culture of monocyte–macrophages
Human (THP-1) monocytes (ECACC 88081201) were maintained in
RPMI 1640 medium containing Ultraglutamine (Lonza, Wokingham,
UK), supplemented with fetal bovine serum (FBS, 10% v/v), HEPES
(10 mmol l1), sodium bicarbonate (0.075%, w/v) and penicillin/strep-
tomycin (50 U ml1; 50 lg ml1, respectively) as previously [20].
Macrophage diﬀerentiation (1.5 · 106 cells well1) was initiated by
addition of phorbol 12-myristate 13-acetate (250 nM) and continued
for 5 days, renewing the medium on alternate days [20]. Murine
peritoneal macrophages were prepared by peritoneal lavage, and
cultured (1.5 · 106 well-1) in DMEM, supplemented as above, for
24 h before experimentation.
2.2. Macrophage experiments
Exogenous human or murine recombinant resistin (Biogenesis,
Poole, UK) (0–100 ng protein ml1; 0–5 nmol l1 dimeric protein)
was added (24 h) in serum-free RPMI 1640 to THP-1 macrophages,
and in serum-free DMEM to murine peritoneal macrophages. This
adipocytokine is certiﬁed as containing <0.1 ng endotoxin lg1 recom-
binant resistin; previous work [19] conﬁrmed that addition of poly-
mixin B does not block the eﬀects of resistin on lipid metabolism.
Low-density lipoprotein (Athens Research, USA) was oxidized by
the addition of copper ions (40 nmol CuSO4 LDL protein mg
1
48 h; EDTA 0.01%) and additions made at 50 lg OxLDL protein
ml1 where indicated; addition of ACAT inhibitor, Sandoz 58-035
(10 lM) was made using DMSO as vehicle and control (<0.1%, v/v).
2.3. Analysis of macrophage lipid syntheses and lipid mass
Incorporation of exogenous [14C]acetic acid (1 l Ci ml1), [3H]oleic
acid (1 lCi ml1; 10 lM [3H]oleate/BSA complex [1:1]) into fatty acid,
cholesterol, cholesteryl esters and triacylglycerol pools were measured
following incubation (24 h) in the presence or absence of resistin as
indicated in legends to ﬁgures. Macrophage lipids were extracted using
hexane:isopropanol (3:2, v/v), dried under N2, and resuspended in iso-
propanol, before separation by t.l.c., using petroleum ether:diethyl
ether:acetic acid (90:30:1, v/v/v) as the mobile phase. Lipids were iden-
tiﬁed by co-migration with authentic standards and incorporation of
radiolabel assessed by scintillation counting. Results are expressed as
pmol or nmol radiolabel incorporated mg1 cell protein. Cellular con-
tent of total, free and esteriﬁed cholesterol, and triacylglycerol, were
measured using Inﬁnity, and Wako reagents (from Alpha Laborato-
ries, Eastleigh, UK); cellular protein mass was determined after solubi-
lization in NaOH ð0:5 mol l1Þ, using the bicinchoninic acid assay
(Pierce, Sigma). Results are expressed as lg lipid mg1 cell protein.
Neutral lipids were visualized by Oil-Red-O staining, using the method
described by Mori et al. [21].
2.4. Measurement of cholesterol eﬄux parameters
Macrophage cholesterol eﬄux was determined essentially as previ-
ously described [20]; in brief, cells were incubated in RPMI 1640 med-
ium containing FBS (10%, v/v) supplemented with [3H]cholesterol
ð0:5 lCi ml1Þ for 24 h. Cells were incubated (1 h) in serum-free
RPMI 1604 medium containing bovine serum albumin (0.1%, w/v),
washed with serum-free RPMI 1640 medium, and eﬄux (24 h) initiated
by the addition of serum-free RPMI medium ± resistin (0–
100 ng ml1; above) and in the presence or absence of human apoAI
ð10 lg ml1Þ. Distributions of radiolabeled cholesterol in cholesterol
and cholesteryl ester pools, media and cells, were determined by t.l.c.
separation. Results are expressed as % cellular cholesterol eﬄux, calcu-
lated as ½dpmðmediaÞ=dpmðcells þ mediaÞ  100%. Secretion of apo-
lipoprotein (apo) E into the culture media was measured using a
commercial Total/Pan ApoE ELISA (supplied by Caltag, Bucking-
ham). Expression of ATP binding cassette transporter A1 (ABCA1)
was determined in cell lysates as described previously [20], except that
a murine monoclonal antibody against human ABCA1 (AbCAM,
Cambridge) was employed (1:1000 dilution).
2.5. Measurement of fatty acid uptake and oxidation
Fatty acid uptake was determined in THP-1 macrophages incubated
for 24 h in serum-free RPMI ± resistin ð50 ng ml1Þ. The medium was
then replaced with serum-free RPMI containing 10 lM [3H]oleic acid
ð1 lCi ml1Þ=BSA complex (1:1), and incubated for 5 min at 37 C.Cells were washed with ice-cold PBS, lipids extracted, separated by
t.l.c. (above) and identiﬁed by co-migration with authentic standards.
Incorporation of radiolabel was assessed by scintillation counting; re-
sults expressed as nmol mg1 cell protein.
Fatty acid oxidation was measured by generation of 14CO2 from
[1-14C]oleic acid, as [5] with some modiﬁcations. Brieﬂy, THP-1 mac-
rophages ð4:5 106Þ were cultured in tissue culture dishes
ð60 15 mmÞ, and incubated in serum-free RPMI medium ± resistin
ð50 ng ml1Þ for 22 h. The medium was replaced with fresh serum-
free RPMI containing [1-14C]oleic acid/BSA complex
ð3 lM; 0:15 lCi ml1Þ  resistin ð50 ng ml1Þ for 2 h, before exchang-
ing the lid of each Petri dish for one containing a Whatman ﬁlter paper
wet with 100 ll of phenylethylamine:methanol (1:1, v/v) to trap 14CO2,
followed by addition of 200 ll of H2SO4 (4 M). Dishes were sealed
with Paraﬁlm and incubated for a further 1 h at 37 C; ﬁlter papers
were removed and their associated radioactivity determined by scintil-
lation counting. Fatty acid uptake (1 h) was assessed, essentially as de-
scribed above, and production of 14CO2 expressed as percent of
[1-14C]oleate internalized.
2.6. Fractional turnover of triacylglycerol (lipolysis and
re-esteriﬁcation)
It was measured as described [22], with some modiﬁcations; human
leukocytes are among the cell types known to utilize glycerol at a sig-
niﬁcant rate [23]. In brief, macrophages ð1:5 106Þ were radiolabeled
by the addition of a mixture of [3H]oleate ð10 lM; 1lCi ml1Þ BSA
complex, and [U-14C]glycerol ð10 lM; 0:3 lCi ml1Þ to RPMI medium
containing FBS (10%). After 4 h, medium was removed, cells washed
with PBS, and lipids extracted from three wells to deﬁne the initial
3H:14C ratio and speciﬁc activity of the macrophage triacylglycerol
pool. Remaining wells of macrophages were incubated in fresh ser-
um-free RPMI medium for 24 h, ±resistin ð50 ng ml1Þ, before wash-
ing and harvesting cellular lipids (above). Triacyglycerol 3H:14C
ratios were determined by t.l.c. (above) and cellular triacylglycerol
mass determined as above. Calculations of fractional turnover of the
intracellular triacylglycerol pool, providing an assessment of lipolysis
and re-esteriﬁcation, were as described [22].
2.7. Analysis of expression of mRNA and protein
Total RNA was extracted from THP-1 macrophages, incubated
±resistin (50 ng ml1, 24 h), and 2 lg of RNA reverse transcribed to
cDNA (Bioline cDNA synthesis kit). Negative controls omitting re-
verse transcriptase were performed for each sample. Oligonucleotide
primers (Eurogentec) were designed against the open reading frames
of the genes encoding ACAT-1 (sense 5 0-CGGGCCTCAGACAATA-
CAAT-3 0 and antisense 5 0-TCTAAGAGAGAGCGCCTTGC-3 0) and
the ‘housekeeping’ enzyme GAPDH (sense 5 0-CCCTTCATTGACCT-
CAACTACATGG-3 0 and antisense 5 0-AGTCTTCTGGGTGG-
CAGTGATGG-3 0). PCR reactions were performed using PCR
Mastermix (AbGene), 100pmol of each primer and 2 ll cDNA tem-
plate; products were separated by agarose gel (1%) electrophoresis,
and compared with a 1 kb hyperladder.
Levels of ACAT-1 protein were determined by immunoblotting
using lysates extracted from cells after treatment ± resistin
(50 ng ml1, 24 h) using anti-ACAT-1 antibody (1:1000 AbCAM,
Cambridge). Levels of phosphorylated acetyl CoA carboxylase
(ACC) were determined in protein lysates prepared from THP-1 mac-
rophages, after exposure to resistin for 5–60 min, and detected using
polyclonal anti-phosphoACC (Ser79) (1:500, Upstate). Lysates
ð20 lgÞ were loaded onto NuPage 10% Bis–tris gels (Invitrogen), trans-
ferred to a PVDF membrane for 90 min at 30 V, before blocking for
1 h (5% w/v Marvel in PBS containing 0.1% Tween) and incubating
with primary antibody overnight at 4 C. Secondary antibodies
(HRP-conjugates) were used at dilutions of 1:1000–1:2000, and bands
detected using ECL detection system (GE Healthcare, Buckingham-
shire). Housekeeping protein GAPDH was used as loading control.3. Statistical analyses
Signiﬁcant (P < 0.05) diﬀerences were determined using re-
peated measures analysis of variance (ANOVA) and Tukey–
Kramer multiple comparison post t-test.
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The eﬀects of chronic treatment (24 h) with exogenous re-
combinant human resistin ð5–100 ng ml1Þ in serum-free
RPMI 1640 medium, in the presence or absence of oxidized
LDL (OxLDL; 50 lg ml1Þ, on macrophage cholesteryl ester
mass is shown in Fig. 1A. Under basal conditions, the macro-
phage cholesteryl ester pool expanded maximally at
5–10 ng ml1 resistin, by 68% ðP < 0:001Þ, and by 130%
ðP < 0:001Þ in the presence of OxLDL (Fig 1A). Similar in-
creases in cholesteryl ester mass were noted when using human
recombinant resistin derived from bacterial (Escherichia coli)
or eukaryotic (HEK293) cells; equivalent increases in lipid
accumulation were also noted using resistin derived from dif-
fering sources. Notably, the eﬀects of resistin and OxLDL on
the macrophage cholesteryl ester pool were not additive in nat-
ure, with smaller relative increases in cholesteryl ester mass ob-
served in incubations containing both resistin and OxLDL. As
expected [19], resistin ð100 ng ml1Þ also induced signiﬁcant
ð< 0:001Þ increases in macrophage triacylglycerol mass under0 1 5 10 50 100
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4880 C. Rae et al. / FEBS Letters 581 (2007) 4877–4883resistin 264.5 ± 16.0 lg mg1 protein; P < 0.05; mean ± SEM;
n = 6) in murine peritoneal macrophages incubated in the ab-
sence of exogenous fatty acid.
The eﬀect of chronic treatment (24 h) with resistin
ð5–100 ng ml1Þ on incorporation of exogenous [3H]oleate
ð10 lM; 1 lCi ml1Þ into the macrophage cholesteryl ester
pool is shown in Fig. 1C. Signiﬁcant increases of 63.4%
ðP < 0:001Þ in incorporation of [3H]oleate into cholesteryl es-
ter were noted at the highest concentration of resistin tested
ð100 ng ml1Þ, reﬂecting the availability of non-esteriﬁed
[3H]oleate within macrophages, which increased by up to
44.1% (53:4 10:4 pmol mg1 cell protein control versus
73:4 12:4 pmol mg1 cell protein; n ¼ 5; P < 0:01) in cells
treated with resistin ð100 ng ml1Þ. Incorporation of [3H]oleate
into triacylglycerol was also signiﬁcantly increased ðP < 0:001Þ
by treatment with resistin (100 ng ml1; 24 h) from 1:50 0:39
to 1:88 0:44 nmol mg1 cell protein ðn ¼ 7Þ. Resistin
ð50 ng ml1Þ induced increases in cholesterol esteriﬁcation
were eﬀectively blocked by addition of Sandoz ACAT inhibi-
tor, 58-035 ð10 lMÞ (Fig. 1D). However, treatment with resi-
stin did not alter the expression of ACAT-1 mRNA or
protein, as assessed by semi-quantitative RT-PCR relative to
GAPDH, and by Western blotting (Fig. 1E).
The increases in cholesterol esteriﬁcation due to resistin
could not be explained by changes in cholesterol biosynthesis
from [14C]acetate (control 346:0 8:94 pmol mg1 cell pro-
tein versus resistin ½50 ng ml1 347:9 6:77 pmol mg1 cell
protein; n ¼ 6, NS) or to altered cholesterol eﬄux to the
‘endogenous’ cholesterol acceptor, apolipoprotein (apo)E
(Table 1). Addition of apoAI ð10 lg ml1Þ signiﬁcantly in-
creased both [3H]cholesterol eﬄux ðP < 0:05Þ and apoE secre-
tion ðP < 0:001Þ, as expected [24], but both parameters were
unaﬀected by the simultaneous addition of resistin to the
medium. Protein levels of ABCA1, ‘gatekeeper’ of cholesterol
eﬄux to apoAI and apoE [25], were not altered in cell lysates
prepared from macrophages treated with resistin
ð5–50 ng ml1Þ for 24 h (data not shown); constant levels of
the housekeeping protein, GAPDH, were observed in all
samples tested. However, chronic treatment with resistin did
signiﬁcantly ðP < 0:05Þ alter the intracellular distribution of
[3H]cholesterol, increasing the [3H]cholesteryl ester pool by
40.3% at 100 ng resistin ml1 (Table 1); this eﬀect of resistin
was reversed by addition of the exogenous cholesterol accep-
tor, apoAI.
Accumulation of cholesteryl esters within macrophage ‘foam
cells’ is, of course, the hallmark of early atheromatous lesions
[26]. Although this is the ﬁrst report that resistin increases
macrophage cholesteryl ester mass, Xu et al. [17] have shown
that expression of resistin is increased by oxidized LDL in hu-
man monocyte-derived macrophages, and that resistin induces
mRNA expression of CD36, which may facilitate uptake of
both oxidized LDL and fatty acids (Fig. 1A, B). This may con-
tribute to the observed increases in macrophage lipid content
reported here, and in previous studies [17,19], and suggests
that resistin may sustain a pro-atherogenic positive feedback
loop within the vascular wall. Other adipokines also impact
upon macrophage cholesterol homeostasis; adiponectin
reduces ACAT-1 expression [27] and limits accumulation of
cholesteryl esters derived from acetylated LDL, by down-reg-
ulating the expression of scavenger receptor AI/II in human
monocyte-derived macrophages [28], and in the presence of
high concentrations of glucose, leptin increases cholesteryl
C. Rae et al. / FEBS Letters 581 (2007) 4877–4883 4881esteriﬁcation and inhibits cholesteryl ester breakdown in mur-
ine J774.2 macrophages [29].
Resistin signiﬁcantly alters fatty acid and triacylglycerol
metabolism in THP-1 macrophages (Fig. 2). Preincubation
(24 h) in the presence of resistin ð50 ng ml1Þ signiﬁcantly en-
hanced the subsequent uptake of [3H]oleate by 28.5%
ðP < 0:05; n ¼ 3Þ (Fig. 2A), possibly by up-regulation of
CD36 [17]. By contrast, prior exposure to the same concentra-
tion of resistin signiﬁcantly decreased fatty acid oxidation by
29% ðP < 0:05; n ¼ 3Þ, as judged by conversion of [1-14C]ole-
ate to ½14CCO2 (Fig. 2B), although no changes in incorpora-
tion of [14C]acetate into the fatty acid pool are noted
(control 42:2 1:53 pmol mg1 cell protein versus resistin
½50 ng ml1 42:3 2:30 pmol mg1 cell protein; n ¼ 6; NS).
The changes in fatty acid metabolism were accompanied by de-
creases in the phosphorylation status of ACC, measured
acutely after 0–60 min exposure to resistin ð50 ng ml1Þ
(Fig. 2C); resistin also decreases ACC phosphorylation and
fatty acid oxidation and induces triacyglycerol accumulation
in rat skeletal muscle cells [5].
These data, together with the enhanced availability of
[3H]oleate observed under steady-state conditions (above),
suggested that resistin-induced increases in fatty acid availabil-
ity might be one factor enhancing cholesterol esteriﬁcation and
increases in macrophage cholesteryl ester mass. We examinedControl Resistin
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Fig. 2. (A) Eﬀect of preincubation in the absence or presence of resistin (5
macrophages; values are mean ± S.E.M. of three experiments; P < 0:05 com
macrophages, previously incubated in the presence or absence of resistin (
experiments; P < 0:05 compared with the control incubation. (C) Phospho
resistin ð50 ng ml1Þ for the indicated periods of time (min); data shown repr
densitometry (bottom); P < 0:05 compared with the start of the experimentthe turnover of triacylglycerol, pre-labeled using [3H]oleate
and [14C]glycerol (Table 2), and noted that the speciﬁc activity
ratio of these two isotopes in the triacylglycerol pool changed
signiﬁcantly during a subsequent 24 h incubation in serum-free
medium, indicating that lipolysis and re-esteriﬁcation had oc-
curred [22]. Overall, the calculated fractional turnover of triac-
ylglycerol (pools/24 h) were 2:029 0:038 ðn ¼ 3Þ in
macrophages incubated under control conditions, and
2:377 0:035 in macrophages co-incubated with resistin
ð50 ng ml1Þ, a signiﬁcant ðP < 0:01Þ increase of 17.2% due
to resistin treatment.
Thus, under basal conditions in our macrophages, where
exogenous fatty acid is not provided and endogenous fatty acid
synthesis not increased, decreased fatty acid oxidation must
contribute to increased availability of fatty acids, driving mac-
rophage cholesteryl ester and triacylglycerol accumulation. In
turn, this implies that macrophage cholesteryl ester and/or tri-
acylglycerol pools undergo cycles of lipolysis and re-esteriﬁca-
tion. We conﬁrmed these macrophages contain a metabolically
active pool of triacylglycerol which undergoes lipolysis under
basal conditions, and that resistin increases the fractional turn-
over of this pool (Table 2). Theoretically, this ﬁnding might
suggest that human resistin, by accelerating the fatty acid/tri-
acylglycerol futile cycle, would reduce the size of intracellular
lipid droplets, as it is proposed to do in adipocytes [30,31].Control Resistin
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.
Table 2
Relative decline in triacylglycerol speciﬁc radioactivity
Control Resistin
Initial cell TAG
Speciﬁc activity 14C ðcpm lg1Þ 21:3 2:5
Speciﬁc activity 3H ðcpm lg1Þ 1772 206
14C:3H ratio 0:0125 0:0012
Final cell TAG
Mass (lg=mg cell protein) 77:1 4:24 85:2 4:25**
Speciﬁc activity 14C ðcpm lg1Þ 6:30 2:30 6:50 2:40
Speciﬁc activity 3H ðcpm lg1Þ 1369 343 1546 394**
14C:3H ratio 0:00432 0:0006 0:00395 0:0006**
14C:3H ratio (% initial cell ratio) 34:2 1:51 31:33 1:62**
Fractional turnover of TAG (pools/24 h) 2:029 0:038 2:377 0:035 **
Macrophages were radiolabeled with [3H]oleate and [14C]glycerol (Section 2) for 4 h to provide the initial cell triacylglycerol 14C:3H speciﬁc activity
ratio. The remaining dishes were incubated for a further 24 h, in serum-free media, and in the presence or absence of resistin ð50 ng ml1Þ to
determine extent of triacyglycerol lipolysis.
**P < 0:01 compared with the control incubation, and are the means ± S.E.M. of three independent experiments.
4882 C. Rae et al. / FEBS Letters 581 (2007) 4877–4883Clearly, however, this is not the case: resistin induced signiﬁ-
cant increases in cholesteryl ester and triacylglycerol mass,
and in Oil-Red-O staining of neutral lipids. Rather, resistin
seems to re-direct the metabolism of non-esteriﬁed fatty acids,
derived from either exogenous sources or from lipolysis of the
endogenous triacylglycerol pool, away from mitochondrial
oxidation and towards (re-)esteriﬁcation into neutral lipid
pools.
In summary, this study shows that resistin, a novel adipo-
cyte- and macrophage-derived protein present within human
and murine atheromatous lesions, may contribute to the ath-
erogenic process by increasing macrophage cholesterol esteriﬁ-
cation and lipid deposition, by mechanisms that increase the
intracellular availability of non-esteriﬁed fatty acids.
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